Literature DB >> 25179091

In vitro testing the potential of a novel chimeric IgG variant for inhibiting collagen fibrils formation in recurrent hereditary gingival fibromatosis: chimeric antibody in a gingival model.

K Gawron1, K Lazarz-Bartyzel, M Lazarz, K Steplewska, K Pyrc, J Potempa, M Chomyszyn-Gajewska.   

Abstract

Gingival fibromatosis is a progressive enlargement of the gingiva. It may hinder oral cavity hygiene and result in underlying bone loss. The long-term benefits of surgery cannot be predicted. On the other hand, alternative, efficient and non-invasive methods are not available at present. The aim of this study was to test the inhibitory effects of a chimeric IgG variant on collagen fibril formation in the cell culture of gingival fibroblasts taken from a patient with hereditary gingival fibromatosis with a high propensity for recurrence. Gingival biopsies were collected from the mandibular gingiva and used for histological evaluation as well as to establish a fibroblast culture. A histological evaluation was made in haematoxylin-eosin and Heidenhain's trichrome stained tissue sections. The inhibitory effect of a chimeric antibody on collagen fibril formation was determined in fibroblast cultures by using a collagen-specific Western blot and immunofluorescent staining. A histological evaluation revealed epithelial acanthosis with singular elongated rete pegs extending into the underlying connective tissue stroma that consisted of locally abundant, irregular collagen bundles. Based on observations with an in vitro model we conclude that a chimeric anti-collagen antibody efficiently inhibits collagen fibril accumulation in cell culture derived from diffuse, hereditary gingival fibromatosis that is characterized by a high propensity for recurrence (high proliferation index). Employing cell cultures from standardized group of patients with recurrent hereditary gingival fibromatosis as well as standarizing relevant 3D (tissue-like) models will be crucial for further tests of the antibody.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25179091

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  7 in total

1.  Analysis of mutations in the SOS-1 gene in two Polish families with hereditary gingival fibromatosis.

Authors:  K Gawron; G Bereta; Z Nowakowska; K Łazarz-Bartyzel; J Potempa; M Chomyszyn-Gajewska; R Górska; P Plakwicz
Journal:  Oral Dis       Date:  2017-05-22       Impact factor: 3.511

2.  Identifying the focuses of hereditary gingival fibromatosis with bioinformatics strategies.

Authors:  Fumin Zheng; Guangtian Chen; Hui Deng
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

3.  Gingival Fibromatosis with Distinctive Facies - A Three Generation Case Report.

Authors:  Sachin Kanagotagi; Sunil Sidana; Sneha Rajguru; Ashvini Padhye
Journal:  J Clin Diagn Res       Date:  2015-05-01

4.  Unusual clinical and histologic findings in a child with mixed dentition with hereditary gingival fibromatosis: a case report.

Authors:  Han Gao; Jun Liang; Xiaoxue Xia; Zhaoming Deng; Zhaoqiang Zhang
Journal:  Transl Pediatr       Date:  2020-02

5.  Gingival Fibromatosis with Significant De Novo Formation of Fibrotic Tissue and a High Rate of Recurrence.

Authors:  Katarzyna Gawron; Katarzyna Łazarz-Bartyzel; Andrzej Fertala; Paweł Plakwicz; Jan Potempa; Maria Chomyszyn-Gajewska
Journal:  Am J Case Rep       Date:  2016-09-09

Review 6.  Clinics and genetic background of hereditary gingival fibromatosis.

Authors:  Karolina Strzelec; Agata Dziedzic; Katarzyna Łazarz-Bartyzel; Aleksander M Grabiec; Ewa Gutmajster; Tomasz Kaczmarzyk; Paweł Plakwicz; Katarzyna Gawron
Journal:  Orphanet J Rare Dis       Date:  2021-11-24       Impact factor: 4.123

Review 7.  Gingival fibromatosis: clinical, molecular and therapeutic issues.

Authors:  Katarzyna Gawron; Katarzyna Łazarz-Bartyzel; Jan Potempa; Maria Chomyszyn-Gajewska
Journal:  Orphanet J Rare Dis       Date:  2016-01-27       Impact factor: 4.123

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.